Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO (MOIO)

NCT05078047 PHASE3 RECRUITING

Immunotherapy (IO), such as treatment with anti-PD-1, PD-L1, or CTLA-4 inhibitors, is a rapidly expanding treatment for multiple metastatic cancers with improved survival for certain cancers. However, the optimal duration of immunotherapies is currently unknown. Our hypothesis is that a reduced dose intensity of IO could be as effective as the current standard treatment in term of prevention of the disease progression. If proved right, this study will have a positive medico-economic impact by reduction of the costs associated with the treatment and the toxicity, and an increase of the patients' quality of life.

Details

Lead sponsor	UNICANCER
Phase	PHASE3
Status	RECRUITING
Enrolment	646
Start date	Tue Mar 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sun Mar 07 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Lung Cancer Metastatic
• Renal Cell Carcinoma
• Head and Neck Cancer
• Triple Negative Breast Cancer
• Merkel Cell Carcinoma
• Hepatocellular Carcinoma
• Melanoma
• Urothelial Carcinoma
• Colorectal Carcinoma With Microsatellite Instability
• Esophageal Squamous Cell Carcinoma

Interventions

• Reduced dose intensity of IO

Countries

France